Edition:
United Kingdom

Ophthotech Corp (OPHT.OQ)

OPHT.OQ on NASDAQ Stock Exchange Global Select Market

2.85USD
13 Dec 2017
Change (% chg)

$0.02 (+0.71%)
Prev Close
$2.83
Open
$2.81
Day's High
$2.89
Day's Low
$2.77
Volume
76,304
Avg. Vol
146,645
52-wk High
$5.48
52-wk Low
$2.24

Chart for

About

Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the... (more)

Overall

Beta: 1.48
Market Cap(Mil.): $92.37
Shares Outstanding(Mil.): 35.94
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Ophthotech Q3 earnings per share $5.25

* Ophthotech reports third quarter 2017 financial and operating results

08 Nov 2017

BRIEF-Ophthotech recieves termination notice from Novartis Pharma

* Ophthotech-On oct 24, co received from Novartis Pharma notice terminating Licensing & Commercialization Agreement between parties dated May 19, 2014 Source text : (http://bit.ly/2gPty5O) Further company coverage:

27 Oct 2017

BRIEF-Ophthotech gives update on programs for treatment of eye diseases

* Ophthotech provides update on Zimura® complement programs for treatment of eye diseases

19 Sep 2017

BRIEF-Ophthotech reports second quarter 2017 financial and operating results

* Q2 earnings per share view $1.05 -- Thomson Reuters I/B/E/S

26 Jul 2017

BRIEF-Ophthotech expands focus with development for ophthalmic orphan diseases

* Ophthotech expands focus with development for ophthalmic orphan diseases

26 Jul 2017

BRIEF-Ophthotech and Novartis Pharma enters into a letter agreement with respect to licensing and commercialization agreement

* Ophthotech - on July 3, co and Novartis Pharma entered into a letter agreement with respect to licensing and commercialization agreement dated May 19, 2014

10 Jul 2017

Competitors

Earnings vs. Estimates